Clinical Oncologist in Hong Kong
Hong Kong
Joined September 2023
- Tweets26
- Following56
- Followers76
- Likes87
Landon Chan retweeted
So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO
These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC.
ascopubs.org/doi/10.1200/JCO…
Landon Chan retweeted
📢New from EORTC-ESTRO OligoCare in
@TheLancetOncol: this 3rd #OligoCare consensus paper recommends preferred primary endpoints for trials of metastasis directed therapies in #oligometastatic cancer, supporting more patient centred & comparable research.
👉bit.ly/3QCihGD
Landon Chan retweeted
@mollylisc and I are looking forward to hosting Conversations In Thoracic Oncology 2026 (#CITO26) 🫁 at @CUHK_MC in 2+ weeks' time in #HongKong!
Welcoming speakers who are #RisingStars 🌟 in #ThoracicOncology from #HongKong 🇭🇰, #Japan 🇯🇵, #Taiwan 🇹🇼, #ChineseMainland 🇨🇳, #Singapore 🇸🇬 and #SouthKorea 🇰🇷.
@stephanieplsaw @DrYujiUehara @TonyMok9 amongst many others!
@apoddc @APCLC_2023 #drugdevelopment @IASLC
Landon Chan retweeted
Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma
@HEP_Journal
doi.org/10.1097/HEP.00000000…
👏Timely guideline
👉still very difficult to treat tumor
@ASCO @myESMO @EASLnews @ILCAnews
Landon Chan retweeted
Happy to share this interactive contouring tutorial for dose-escalated RT in locally advanced pancreas ca, which follows our NRG consensus contouring atlas.
Thank you @johnroubil, @dsouzl, @aiims2738, & the @eContourRadOnc team for working on this case!
econtour.org/cases/180
Landon Chan retweeted
Link to contouring atlas:
redjournal.org/article/S0360…
Landon Chan retweeted
Like PROSPECT, the RT arm in CONVERT received less chemo. Not only was planned # of cycles less (6 v 8), but ~25% never received ANY multiagent chemo.
Hence trial compensates for RT omission by delivering more chemo. In that light, similar DFS/OS (even w N2) actually remarkable.
Can we safely omit radiation in selected locally advanced rectal cancer?
The CONVERT trial randomized mesorectal fascia–negative patients to neoadjuvant CAPOX vs ChTR
3-year local control: 96.3% vs 97.4%.
Non-inferiority was not formally met ⚠️
DFS/OS were similar between arms.
Long-term toxicity favored ChT alone.
Careful selection may allow de-escalation w/o compromising outcomes.
ascopubs.org/doi/pdf/10.1200… @JCO_ASCO @OncoAlert
Happy to share our review article on Recent advancements for RT in HCC is now online in ESMO Gastrointestinal Oncology!😃
Emerging indications for RT include bridging to transplant, combining with systemic therapy, and its use in oligo-met/PD cases!
sciencedirect.com/science/ar…
4
160
Landon Chan retweeted
Recent advancements in radiotherapy for hepatocellular carcinoma
For years, RT played only a limited role in HCC management.
Today, SBRT can achieve >90% 2 year local control with RILD <5% (Radiation-Induced Liver Disease)
Proton therapy reports ~88% 3-year local control with low hepatic toxicity.
Not universally adopted, but difficult to ignore with modern data.
esmogastro.org/article/S2949… @OncoAlert
Landon Chan retweeted
🫁 Catching up on #ASCO25 news?
⭐ Don't miss this insightful interview with @mollylisc on the LC-SHIELD study, which is evaluating AI-based lung cancer screening in people who have never smoked but are at a high risk for lung cancer.
➡️ Watch: buff.ly/PvgD9rw
#lcsm
Landon Chan retweeted
Checkpoint inhibitors are now standard in advanced HCC, but resistance is common. This review explores how TACE, radiation, and novel combos (triplets, bispecifics, vaccines) may expand efficacy and indications.
Read here: journals.sagepub.com/doi/epd…
Landon Chan retweeted
We are thrilled to have our new #Dean of @CUHKMedicine @pwychiu visit our small (but very productive! 🤗) Department of #ClinicalOncology @CUHKofficial to discuss future strategic directions and plans. @TonyMok9 #AnthonyChan #WinnieYeo #BrigetteMa #StephenChan @mollylisc @LandonLChan #KelvinYan
Happy to share our team’s work published on JHep! This is the first prospective trial testing cabozantinib in the post-IO setting for HCC. Hope this will provide a new standard and benchmark for future trials!
@StephenLChan1 @changhoon_yoo Dr CJ Kyung
journal-of-hepatology.eu/art…
Landon Chan retweeted
Congratulations @CUHKofficial Landon Chan, and thank you to all colleagues from Zhongshan Shanghai @NUSingapore Zhongshan Xiamen for joining the quarterly @MSKCancerCenter @MSK_DeptOfMed East West #Liver #HCC Rounds
Landon Chan retweeted
Great experience and amazing interaction between participant’s & faculties from👉
🇵🇭🇧🇩🇮🇳🇭🇰🇹🇼🇻🇳🇳🇵🇮🇩🇵🇰🇺🇿🇲🇾🇲🇲🇯🇵🇲🇳 & 🇹🇼 🇩🇪🇯🇵🇸🇬🇬🇧 (🇪🇸🇨🇦+/- 🇦🇷)
Take Home Message
👌 multidisciplinar approach is key
👉 The 🧰 of the #BCLC2022 reflects the Tumor Board Decision
🔝New era #IO & #LRT
Heading✈️home from Singapore
Many🙏 to ESMO to organize this great advanced course on HCC
👏Excellent lecturers & speakers
👍great discussions with esteemed colleagues from all over ASIA
👉Lots of opportunities but also many inequalities and challenges in access to effective medicines in HCC
@myESMO
Landon Chan retweeted
Heading✈️home from Singapore
Many🙏 to ESMO to organize this great advanced course on HCC
👏Excellent lecturers & speakers
👍great discussions with esteemed colleagues from all over ASIA
👉Lots of opportunities but also many inequalities and challenges in access to effective medicines in HCC
@myESMO
2nd day in ESMO Advanced Course on HCC: local and systemic therapy options for advanced HCC patients 🇸🇬
4
5
392
Landon Chan retweeted
#ESMOAsia23 Poster: Genome guided targeted therapy improves survival post-osimertinib failure. Retrospective data.
30% (21/68) pts had actionable resistance. GGTT (n=17, 13 with METamp) ⬆️TTF (HR 0.19) & ⬆️OS (HR 0.27) c/f chemotherapy (n=209).
@CUHKMedicine
@EGFRResisters
Happy to share my *first* poster in international conference on the recurrence pattern of HCC following curative surgery and RFA in the era of effective antivirals! Thx for the support!
@StephenLChan1 @mollylisc @TonyMok9
